Form 4: Tharimmune CEO Acquires 4,600 Shares in Open Market Purchase

Tharimmune CEO Randy Milby purchased 4,600 shares of common stock at $2.12 per share on December 19, 2024.

Summary

• Tharimmune's CEO, Randy Milby, acquired 4,600 shares of the company's common stock on December 19, 2024.
• The purchase was made at a price of $2.12 per share.
• Following this transaction, Mr. Milby directly owns a total of 17,534 shares of Tharimmune common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO's share purchase, which is generally seen as a sign of confidence. However, it's a relatively small transaction and doesn't provide a strong signal.

Positives

• The CEO's purchase of shares may indicate confidence in the company's future prospects.
• The purchase increases the CEO's alignment with shareholder interests.

Industry Context

Insider trading activity is closely monitored by regulators and investors as it can provide insights into management's view of the company's prospects. This purchase by the CEO is a positive signal.

Comparison to Industry Standards

• Insider purchases are generally viewed positively by the market, especially when made by top executives like the CEO.
• This type of transaction is common and is reported via SEC Form 4 filings.
• The size of the purchase, 4,600 shares, is relatively small compared to some insider transactions, but still significant as it represents a personal investment by the CEO.

Stakeholder Impact

• The share purchase may positively influence investor confidence.
• The purchase aligns the CEO's interests with those of shareholders.

Key Dates

Keywords

Tharimmune, Randy Milby, insider trading, share purchase, common stock, CEO, SEC Form 4